PCA
CTKB icon

Pallas Capital Advisors’s Cytek Biosciences CTKB Stock Holding History

Pallas Capital Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.9K Sell
11,269
-2,195
-16% -$9.37K ﹤0.01% 989
2026
Q1 		$58.8K Sell
13,464
-489
-4% -$2.31K ﹤0.01% 824
2025
Q4 		$70.5K Sell
13,953
-452
-3% -$2.1K ﹤0.01% 857
2025
Q3 		$50K Buy
14,405
+336
+2% +$1.26K ﹤0.01% 848
2025
Q2 		$47.8K Buy
+14,069
New +$46.9K ﹤0.01% 828

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Pallas Capital Advisors's CTKB Position: Q2 2026 in Review

Pallas Capital Advisors reduced its Cytek Biosciences (CTKB) stake by 16% in Q2 2026, selling an estimated $9.37K and leaving 11,269 shares worth $49.9K. The position accounts for ﹤0.01% of the portfolio, ranked #989.

Pallas Capital Advisors first reported a position in CTKB in Q2 2025 and has held it in 5 quarters since. The position peaked at $70.5K in Q4 2025. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Pallas Capital Advisors held 11,269 shares of Cytek Biosciences worth $49.9K as of Q2 2026.
  • Pallas Capital Advisors sold 2,195 Cytek Biosciences shares in Q2 2026, an estimated $9.37K.
  • Cytek Biosciences made up ﹤0.01% of Pallas Capital Advisors's portfolio in Q2 2026, its #989 holding.
  • Pallas Capital Advisors first reported a position in Cytek Biosciences in Q2 2025 and has held it in 5 quarters since.
  • Pallas Capital Advisors's Cytek Biosciences position peaked at $70.5K in Q4 2025.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.